Glofitamab & TALAPRO - 2
Jun 22, 2023•13 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This week's Pod looks at the 2nd CD20-CD3 bispecific T-Cell engager approved this year (or at all), glofitamab, and the TALAPRO-2 study of combining talazoparib to enzalutaimide.
TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3
For the best experience, listen in Metacast app for iOS or Android